Losmapimod Fails at FSHD Trial’s Primary Goal, But Shows Potential

Losmapimod Fails at FSHD Trial’s Primary Goal, But Shows Potential

297934

Losmapimod Fails at FSHD Trial’s Primary Goal, But Shows Potential

Oral losmapimod, an investigational treatment for people with facioscapulohumeral muscular dystrophy (FSHD), showed clinically relevant benefits over a placebo on multiple measures of disease progression and patient-reported outcomes after almost a year, according to data from the ReDUX4 Phase 2b clinical trial. But the therapy failed to reach trial’s primary goal: changes in the activity of the DUX4 gene in affected skeletal muscle.  According to Fulcrum Therapeutics, losmapimod’s developer, this “experimental biomarker endpoint” was hampered by several…

You must be logged in to read/download the full post.